Maxcyte (MXCT) Net Cash Flow (2020 - 2026)

Maxcyte (MXCT) has reported Net Cash Flow for 7 consecutive years, with $485000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 105.94% year-over-year to $485000.0 in Q2 2026; TTM through Jun 2026 was -$183000.0, a 99.18% increase from a year earlier, with the FY2025 full-year figure at -$7.8 million, up 58.01% from the prior year.
• Net Cash Flow was $485000.0 for Q2 2026 at Maxcyte, up from -$5.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $192.0 million in Q1 2022 and troughed at -$130.6 million in Q2 2022.
• A 5-year average of -$1.8 million and a median of -$3.6 million in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 220.27% in 2022, down 406.95% in 2022.
• Over 5 years, Net Cash Flow stood at -$32.0 million in 2022, then soared by 91.66% to -$2.7 million in 2023, then plunged by 240.49% to -$9.1 million in 2024, then soared by 178.16% to $7.1 million in 2025, then sank by 93.16% to $485000.0 in 2026.
• The last three Net Cash Flow figures came in at $485000.0 (Q2 2026), -$5.5 million (Q1 2026), and $7.1 million (Q4 2025), per Business Quant data.